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OBJECTIVES We sought to investigate the potential benefit of thrombolytic therapy (TT) and intra-aortic
balloon pump counterpulsation (IABP) on in-hospital mortality rates of patients enrolled in
a prospective, multi-center Registry of acute myocardial infarction (MI) complicated by
cardiogenic shock (CS).
BACKGROUND Retrospective studies suggest that patients suffering from CS due to MI have lower
in-hospital mortality rates when IABP support is added to TT. This hypothesis has not
heretofore been examined prospectively in a study devoted to CS.
METHODS Of 1,190 patients enrolled at 36 participating centers, 884 patients had CS due to
predominant left ventricular (LV) failure. Excluding 26 patients with IABP placed prior to
shock onset and 2 patients with incomplete data, 856 patients were evaluated regarding TT
and IABP utilization. Treatments, selected by local physicians, fell into four categories: no
TT, no IABP (33%; n 5 285); IABP only (33%; n 5 279); TT only (15%; n 5 132); and
TT and IABP (19%; n 5 160).
RESULTS Patients in CS treated with TT had a lower in-hospital mortality than those who did not
receive TT (54% vs. 64%, p 5 0.005), and those selected for IABP had a lower in-hospital
mortality than those who did not receive IABP (50% vs. 72%, p , 0.0001). Furthermore,
there was a significant difference in in-hospital mortality among the four treatment groups:
TT 1 IABP (47%), IABP only (52%), TT only (63%), no TT, no IABP (77%) (p , 0.0001).
Patients receiving early IABP (#6 h after thrombolytic therapy, n 5 72) had in-hospital
mortality similar to those with late IABP (53% vs. 41%, n 5 64, respectively, p 5 0.172).
Revascularization rates differed among the four groups: no TT, no IABP (18%); IABP only
(70%); TT only (20%); TT and IABP (68%, p , 0.0001); this influenced in-hospital
mortality significantly (39% with revascularization vs. 78% without revascularization, p ,
0.0001).
CONCLUSIONS Treatment of patients in cardiogenic shock due to predominant LV failure with TT, IABP
and revascularization by PTCA/CABG was associated with lower in-hospital mortality rates
than standard medical therapy in this Registry. For hospitals without revascularization
capability, a strategy of early TT and IABP followed by immediate transfer for PTCA or
CABG may be appropriate. However, selection bias is evident and further investigation is
required. (J Am Coll Cardiol 2000;36:1123–9) © 2000 by the American College of
Cardiology
Small retrospective studies of patients suffering from acute
myocardial infarction (MI) complicated by cardiogenic
shock (CS) suggest that the addition of intra-aortic balloon
pump counterpulsation (IABP) to thrombolytic therapy
(TT) reduces in-hospital mortality rates, compared with TT
treatment alone (1–4). Furthermore, the large nonrandom-
ized National Registry of Myocardial Infarction study re-
ported lower mortality rates in patients treated with TT
combined with IABP (49%) compared to TT alone (69%)
(5). However, in the GUSTO (Global Utilization of Strep-
tokinase and tPA for Occluded Coronary Arteries) throm-
bolytic trial, there was only a trend toward reduced in-
hospital and 30-day mortality in a subset of patients
presenting with CS who were treated with TT followed by
early IABP (6). Theoretically, IABP should improve coro-
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nary flow and patency after TT by augmenting diastolic
perfusion pressure and unloading the left ventricle (LV).
Nonrandomized studies also suggest that revasculariza-
tion of patients in CS with percutaneous transluminal
coronary angioplasty (PTCA) or coronary artery bypass
graft surgery (CABG) may also reduce mortality (7–21).
Recently the multicenter randomized trial, SHould we
emergently revascularize Occluded Coronaries for cardio-
genic shocK? (SHOCK Trial), demonstrated that emer-
gency early revascularization with PTCA or CABG im-
proves six-month and one-year survival in patients with CS
due to LV failure, compared with patients treated with
initial medical stabilization (22–24). However, the smaller
and non-significant mortality difference between the groups
at hospital discharge and 30 days may have resulted partially
from the relatively low 30-day mortality observed in the
initial medical stabilization group, in which there was a high
rate of IABP and TT use. The concurrent SHOCK Trial
Registry of patients with suspected CS complicating acute
MI who were not randomized affords the opportunity to
assess the impact of IABP and TT on mortality in the
broader CS population. This report describes the clinical,
hemodynamic and angiographic characteristics, as well as
the procedure utilization and in-hospital mortality rates, of
patients receiving four different treatments used at either the
primary or tertiary referral site: no TT, no IABP; IABP
only; TT only; and TT and IABP.
METHODS
Patient population. Patients with suspected CS compli-
cating acute MI, whether meeting strict trial criteria for CS
or not, were prospectively registered at 36 SHOCK Trial
Registry institutions after obtaining approval of the com-
mittee on human research at each center. The criteria for
enrollment and the definitions used in the SHOCK Trial
Registry are described in the report on the overall findings
of the SHOCK Trial Registry (25). Of the 1,190 patients
enrolled in the SHOCK Trial Registry, 884 (74%) had CS
due to predominant LV failure. Predominant LV failure
was designated as the etiology of CS when none of the
following major shock categories was indicated: acute severe
mitral regurgitation, ventricular septal rupture, isolated right
ventricular failure, cardiac tamponade or rupture, prior
severe valvular heart disease, excess beta or calcium channel
blockade, dilated cardiomyopathy, CS associated with re-
cent hemorrhage or resulting from a cardiac catheterization
laboratory complication or shock due to other causes (e.g.,
sepsis, anaphylaxis). This analysis was based on 856 patients
because of the exclusion of 26 patients with IABP placed
prior to shock onset and 2 patients with incomplete TT and
IABP data.
Data collection. Data were abstracted from the medical
record by SHOCK study coordinators, who were centrally
trained to complete standardized study report forms. Patient
characteristics, MI location, hemodynamics, procedure uti-
lization and vital status at hospital discharge were recorded.
Cardiac catheterization and angioplasty reports were sent to
the Clinical Coordinating Center for abstraction and cen-
tralized completion of a standardized form. The following
variables were collected only on the revised study report
forms and are available for a maximum of 615 patients:
medication usage, left ventricular ejection fraction (LVEF),
pulmonary artery pressures, pulmonary edema, history of
elevated lipids and history of peripheral vascular disease.
Statistical methods. Groups were compared using the
Fisher exact test for categorical variables, the Wilcoxon rank
sum test for ordinal and non-normally distributed continu-
ous variables, and Student t-test for normally distributed
continuous variables. When four groups were being com-
pared, continuous variables were evaluated using analysis of
variance and the Kruskal-Wallis test. When a significant
difference among the four groups was identified, a Bonfer-
roni correction (significance level 0.017) was used to com-
pare the TT-and-IABP group to each of the other three
groups. In-hospital mortality for all patients and for revas-
cularized and nonrevascularized patients was analyzed sep-
arately using logistic regression, with main effects for TT
and IABP status and an interaction term of the two effects
to evaluate whether the impact of TT was independent of
IABP use. Multivariate modeling evaluated all variables that
differed among the four groups with a p value of #0.20. All
analyses were conducted using the Statistical Analysis Sys-
tem (SAS Institute, Cary, North Carolina).
RESULTS
Patient characteristics. The patient characteristics for the
four treatment groups are summarized in Table 1. Patients
treated with TT and IABP were significantly younger than
patients in all other groups and less likely to have the risk
factors of prior MI, congestive heart failure, renal insuffi-
ciency or peripheral vascular disease, compared with pa-
tients who received neither TT or IABP. Patients treated
with IABP were almost twice as likely to be transferred to a
SHOCK Trial tertiary medical center (55% vs. 30%, p ,
0.001). There was no significant difference in the time from
MI to shock in the patients receiving the different treat-
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CK 5 creatine phosphokinase
CS 5 cardiogenic shock
IABP 5 intra-aortic balloon pump
LV 5 left ventricular, left ventricle
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
SHOCK 5 SHould we emergently revascularize
Occluded Coronaries for cardiogenic shocK?
TT 5 thrombolytic therapy
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ments. Patients who did not receive TT or IABP were less
likely to have chest pain at presentation (76% vs. 87% with
TT and/or IABP, p , 0.001) (Table 2). Patients receiving
IABP support were more likely to be put on a ventilator or
receive inotropic support (p , 0.001).
ECG characteristics and CK values. Ninety-five percent
of the patients receiving thrombolytics had ST elevation in
two or more leads, significantly more than the groups
without thrombolytics (61%, p , 0.0001). However, only
45% of the patients with ST elevation received thrombolyt-
ics. The distribution of MI location, however, was similar
among the four groups (Table 3). The median highest CK
and its ratio to the upper limit of the local laboratory normal
value were significantly higher in the group receiving TT
and IABP support, compared to each of the other three
groups (p , 0.001).
Hemodynamic and angiographic characteristics. Systolic
and diastolic blood pressure, cardiac index, LVEF, and
pulmonary arterial and wedge pressure were similar among
the four treatment groups (Table 4). There was a significant,
but not clinically relevant, difference in heart rate among
patients who received the four treatments. Right heart
catheterization was more likely to be performed if IABP
support was chosen (80% vs. 47%, p , 0.001). Patients who
were treated with IABP were also more likely to receive
coronary angiography (p , 0.001) and were more likely to
have left main disease (19% vs. 9%, p 5 0.021). The number
of diseased vessels ($50% stenosis) was similar across all
treatment groups.
In-hospital treatment and outcome. Thrombolytic ther-
apy (with or without IABP) was associated with a lower
in-hospital mortality rate than no TT (54% vs. 64%, odds
ratio [OR] 0.66, p 5 0.005) even after adjustment for age
and revascularization status (OR 0.70, p 5 0.027) (Table 5).
Intra-aortic balloon pump use was also associated with a
lower mortality rate than no IABP (50% vs. 72%, p ,
0.0001) because of the higher rate of attempted revascular-
ization in the IABP group (IABP vs. no IABP mortality,
p 5 0.313 after adjustment for revascularization). Among
patients treated with IABP, those with early IABP support
(#6 h post-lytic, n 5 72) had an in-hospital mortality rate
similar to that of patients in whom an IABP was placed later
(.6 h, n 5 64): 53% vs. 41%, respectively (p 5 0.172).
In-hospital mortality rates of the four TT/IABP groups
differed significantly (p , 0.0001). In particular, patients in
CS selected for combined TT and IABP treatment had a
mortality rate of 47%, significantly lower than the 63%
mortality of patients receiving TT only (p 5 0.007).
Table 1. Baseline Characteristics of Patients With CS Due to Predominant LV Failure
No TT
No IABP IABP Only TT Only TT 1 IABP p Value
n 285 279 132 160 —
Age 73 6 11 66 6 11 71 6 12 63 6 12* 0.0001
Male 59% 66% 62% 69% 0.138
History of hypertension 57% 47% 53% 45% 0.046
Diabetes 38% 33% 25% 28% 0.039
Smoking 50% 55% 43% 56% 0.126
History of elev. lipids (n 5 427) 32% 45% 32% 47% 0.031
History of CHF 30% 16% 17% 12%* , 0.0001
Transfer 28% 53% 33% 60% , 0.0001
History of MI 49% 42% 36% 24% , 0.0001
History of PTCA 6% 10% 8% 3% 0.050
History of CABG 12% 12% 5% 5% 0.015
History of renal insuf. 19% 7% 8% 6% 0.0001
History of PVD (n 5 543) 29% 15% 14% 13% 0.0007
*p , 0.05 TT only vs. TT and IABP.
CABG 5 coronary artery bypass surgery; MI 5 myocardial infarction; PTCA 5 any percutaneous coronary intervention
(balloon, stent, etc.); PVD 5 peripheral vascular disease.




No IABP IABP only TT only TT 1 IABP p Value
n 285 279 132 160 —
MI to shock (median, h) 7.7 4.8 7.3 5.0 0.702
Chest pain 76% 85% 89% 88% 0.001
Pulmonary edema on
X-ray, (n 5 608)
53% 65% 61% 57% 0.126
Ventilator 72% 83% 55% 86%* , 0.0001
Inotropes (n 5 615) 63% 79% 62% 79%* 0.0004
Vasopressors (n 5 615) 96% 94% 95% 100%* 0.030
*p , 0.05 TT only vs. TT 1 IABP.
MI 5 myocardial infarction.
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Differences among the four groups persisted even after
adjustment for patient (but not treatment) differences
among the four groups, including age, prior MI, transfer
status and chest pain at presentation (p 5 0.002). After
adjustment for treatment (ventilator use and revasculariza-
tion), there was no difference in mortality among the four
groups (p 5 0.378). However, when examining the impact
of TT and IABP therapy on mortality separately for
revascularized and nonrevascularized patients, patients se-
lected to undergo PTCA or CABG had lower in-hospital
mortality than patients who did not undergo revasculariza-
tion (39% vs. 78%, p , 0.0001).
In patients undergoing revascularization (Fig. 1), TT was
associated with the lowest mortality in the absence of IABP
support (48% mortality for n 5 52 with TT, 95% confi-
dence interval [CI] 35% to 62%, vs. 19% mortality for n 5
27 with no TT, 95% CI 4% to 33%). By contrast, mortality
was similar for the TT and no-TT groups when IABP
support was used: 41% mortality for n 5 195 with TT
versus 37% mortality for n 5 109 with no TT (TT by IABP
interaction p 5 0.048). However, after adjusting for age,
transfer status, and heart rate, there was no significant
differential effect of IABP use on mortality (no TT:TT ORs
for death 5 1.74 without IABP and 1.07 with IABP,
interaction p 5 0.128). A subgroup analysis of patients
undergoing PTCA was also conducted to examine the effect
of unloading with IABP. There was no difference in
in-hospital mortality for patients unloaded with IABP prior
Table 3. ECG Characteristics and CK Values of Patients With CS Caused by Predominant
LV Failure
No TT
No IABP IABP only TT only TT 1 IABP p Value
n 285 279 132 160 —
ST elevation 56% 66% 94% 96% , 0.0001
New LBBB 17% 10% 6% 4% 0.0002
MI location
Anterior 55% 59% 63% 57% 0.458
Inferior 45% 43% 40% 48% 0.347
Posterior 17% 18% 15% 21% 0.663
Lateral 37% 32% 31% 28% 0.276
Apical 9% 8% 9% 13% 0.428
Multiple 50% 48% 45% 53% 0.593
Median highest CK 1,059 1,939 1,992 3,126* 0.0001
Median CK/Upper
Normal limit
5.1 9.7 9.7 14.1* 0.0001
*p , 0.05 TT only vs. TT 1 IABP.
CK 5 creatine phosphokinase; LBBB 5 left bundle branch block; MI 5 myocardial infarction.




No IABP IABP only TT only TT 1 IABP p Value
n 285 279 132 160 —
Systolic BP 88 6 27 89 6 21 85 6 19 88 6 21 0.116
Diastolic BP 53 6 18 54 6 18 52 6 16 52 6 16 0.755
Heart rate 94 6 26 98 6 26 88 6 25 97 6 24* 0.004
RH cath performed
(n 5 549) 47% 80% 47% 81% , 0.0001
CI (n 5 393) 1.9 6 0.6 2.1 6 0.8 2.1 6 0.8 2.0 6 0.8 0.264
PCWP (n 5 516) 23 6 9 24 6 9 22 6 7 24 6 8 0.425
PA systolic (n 5 328) 43 6 12 42 6 15 40 6 10 38 6 12 0.063
PA diastolic (n 5 330) 24 6 6 25 6 9 23 6 8 23 6 8 0.321
LVEF (%) (n 5 325) 32 6 13 28 6 12 32 6 11 31 6 14 0.086
Coronary angiography performed 29% 89% 36% 89%* , 0.0001
(n) 79 242 41 136
LM disease 11% 20% 7% 17% 0.104
Number of diseased vessels 0.203
0 1% 1% 2% 0%
1 23% 16% 29% 29%
2 22% 22% 17% 18%
3 54% 60% 51% 53%
*p , 0.05 TT only vs. TT 1 IABP. Hemodynamic variables were often recorded on support measures (mean 6 SD).
BP 5 blood pressure; CI 5 cardiac index; LM 5 left main coronary artery; LVEF 5 left ventricular ejection fraction; PA
5 pulmonary artery; PCWP 5 pulmonary capillary wedge pressure; RH 5 right heart; VD 5 vessels diseased.
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to PTCA (n 5 98; 47% mortality) when compared with 1)
those treated with IABP after PTCA (n 5 95; 47%
mortality) and 2) patients treated with PTCA without
IABP (n 5 56; 46% mortality).
In patients not undergoing revascularization (Fig. 1), TT
was associated with lower mortality (72% with TT, com-
pared with 81% without TT, p 5 0.044); there was no
evidence of an interaction of IABP and TT use (interaction
p 5 0.785).
DISCUSSION
Benefit of thrombolysis in CS. In this cohort of prospec-
tive, multicenter Registry patients with CS due to predom-
inant LV failure, those treated with TT had lower in-
hospital mortality than those who did not receive TT. This
is a contrast to previous reports from large-scale thrombo-
lytic trials. For example, in the GISSI-1 Trial (26), patients
in Killip class IV had high in-hospital mortality with no
difference between control patients and those treated with
streptokinase (69.9% vs. 71.1%). However, in the Fibrino-
lytic Therapy Trialist overview (27), patients with pump
failure as evidenced by both a systolic blood pressure below
100 mm Hg and a heart rate above 100 beats/min had 7
lives saved per 100 patients treated with TT. Because of the
small sample size in that trial, the difference was not
significant. In this study, the number of patients analyzed
with CS due to predominant LV failure is larger (n 5 856),
and there was an absolute benefit of 10 percentage points.
Overall, those patients treated with TT did better than
those without TT, even after adjustment for age and
revascularization status. The lowest mortality rate (19%)
was observed with the treatment of TT alone followed by
revascularization. Most likely, these were patients in CS
who promptly reperfused and were then revascularized later
in their hospitalizations.
Benefit of IABP. As in prior retrospective studies (1–5),
this prospective Registry demonstrated that patients treated
with the combination of IABP support and TT had the
lowest observed in-hospital mortality. However, this was
not significantly different from the mortality of patients
treated with IABP alone. There was no significant interac-
tion of IABP and TT in both revascularized and nonrevas-
cularized subgroups of patients after adjustment for patient
characteristics. In the largest of the prior studies, in which
21,178 patients were identified and 6,993 (32%) received
IABP, the use of an IABP was associated with a lower
in-hospital mortality rate in patients who received TT
(49%), compared with those who did not receive TT (69%)
(5). Thus, the observations of these two large registries
support the theory that IABP improves survival after TT by
augmenting diastolic perfusion pressure and unloading the
LV. Experimental studies demonstrate that unloading the
LV during ischemia and reperfusion resulted in greater
infarct salvage, compared with reperfusion alone (28). The
lack of difference in in-hospital mortality between IABP
unloading prior to, versus after, PTCA revascularization
may result from differences in patient selection. The higher
CK level in the group receiving TT and IABP may have
Figure 1. In-hospital mortality rates of SHOCK Trial Registry patients with predominant left ventricular failure. Patients receiving thrombolytic therapy
had significantly lower mortality than those not receiving thrombolytic therapy in the overall cohort (p 5 0.005), and this benefit was independent of IABP
use (interaction p 5 0.126). There was a significant difference in in-hospital mortality among the 4 subsets of patients treated with thrombolysis with IABP,
thrombolysis without IABP, IABP alone or neither. Treatments were selected by local physicians. In each of these subsets, patients who underwent
revascularization had lower mortality than those who were not revascularized (p , 0.0002).
Table 5. In-hospital Treatment of Patients With CS Due to Predominant LV Failure
Variable
No TT
No IABP IABP only TT only TT 1 IABP p Value
n 285 279 132 160 —
PTCA 15% 47% 16% 51%* , 0.0001
CABG 4% 26% 5% 23%* , 0.0001
PTCA or CABG 18% 70% 21% 68%* , 0.0001
*p , 0.05 TT only vs. TT 1 IABP.
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resulted from “early washout” from a patent artery. Treat-
ment with early IABP support (within 6 h after TT
administration) was associated with an in-hospital mortality
rate of 53%, compared with 41% in patients treated with
later IABP support (.6 h); these rates were not significantly
different. This observation may also represent a selection
bias, because early IABP support may have been performed
sooner if the patients were deteriorating hemodynamically
and were at a greater imminent risk of death.
Benefit of revascularization. In the nonrandomized Reg-
istry portion of the SHOCK Trial, revascularization at any
time during the hospitalization was associated with the
largest difference in in-hospital mortality (39% revascular-
ized vs. 78% nonrevascularized). It is possible that the
less-than-expected reduction in the 30-day mortality rate by
emergency revascularization (22) in the randomized
SHOCK Trial may be partly explained by the relatively low
30-day mortality observed in the initial medical stabilization
group; this, in turn, may have resulted from the high rate of
IABP use (86%), TT use (63%) and delayed revasculariza-
tion (25%).
Study limitations. Marked differences in patient charac-
teristics certainly contributed to the selection of different
treatments and the final clinical outcome. The differences
noted in these clinical factors suggest that patients selected
for IABP/TT were a lower-risk group who may have been
pre-selected for a more favorable outcome by virtue of their
younger age, less comorbid disease, lower likelihood of a
prior MI and likely, other factors not explicitly measured in
this study.
Implications. The randomized SHOCK Trial demon-
strated that 6 and 12 month mortality was lower with a
strategy of emergency early revascularization, compared
with initial medical stabilization including IABP and TT.
However, IABP and TT may be appropriate initial therapy
at hospitals without revascularization facilities, if followed
by prompt transfer to tertiary care centers. This remains to
be demonstrated in a randomized trial.
Conclusions. This SHOCK Trial Registry of 856 patients
represents the largest prospectively collected series of pa-
tients in CS due to predominant LV failure that examines
the outcome of various treatments and combinations of
therapeutic options. Revascularization by PTCA/CABG,
IABP unloading and, to a lesser extent, TT was associated
with lower in-hospital mortality rates than treatment with
standard medical therapy.
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